$29.87+1.77 (+6.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
UroGen Pharma (URGN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~23.0%/yr (FY21→FY25), net margin −139.8%. Worth your attention in FY25: Share count (+117.8%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)▲21.4%
109.8
FY21→FY25CAGR +23.0%/yr
Net income ($M)▼21.0%
−153.5
FY21→FY25CAGR —
Free cash flow ($M)▼67.7%
−162.7
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+117.8%
22.3mn → 48.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$289.0K
steady at 0.3% of revenue (−2.0% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-140¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 89.3% → 88.7%. Net margin -139.8% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 250,253.0 | 109,788.0 | 90,398.0 | 82,713.0 | 64,357.0 | 48,042.0 | ▲21.4% | +23.0% |
Cost of revenue | 21,502.0 | 12,447.0 | 8,881.0 | 9,361.0 | 7,654.0 | 5,157.0 | ▲40.2% | +24.6% |
Gross profit | 228,751.0 | 97,341.0 | 81,517.0 | 73,352.0 | 56,703.0 | 42,885.0 | ▲19.4% | +22.7% |
Research & development | 73,211.0 | 67,107.0 | 57,145.0 | 45,614.0 | 52,906.0 | 47,642.0 | ▲17.4% | +8.9% |
Selling, general & admin | 186,478.0 | 155,097.0 | 121,154.0 | 93,274.0 | 82,838.0 | 87,535.0 | ▲28.0% | +15.4% |
Total operating expenses | 259,689.0 | 222,204.0 | 178,299.0 | 138,888.0 | 135,744.0 | 135,177.0 | ▲24.6% | +13.2% |
Operating incomefeeds ROC rank | −30,938.0 | −124,863.0 | −96,782.0 | −65,536.0 | −79,041.0 | −92,292.0 | ▼29.0% | — |
Other income, net | −33,215.0 | −28,553.0 | −27,260.0 | −32,788.0 | −28,987.0 | −17,079.0 | — | — |
Pretax income | −64,153.0 | −153,416.0 | −124,042.0 | −98,324.0 | −108,028.0 | −109,371.0 | ▼23.7% | — |
Income tax | 1,598.0 | 78.0 | 2,832.0 | 3,920.0 | 1,755.0 | 1,449.0 | ▼97.2% | −51.8% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −65,751.0 | −153,494.0 | −126,874.0 | −102,244.0 | −109,783.0 | −110,820.0 | ▼21.0% | — |
| Per share | ||||||||
Diluted shares (mn) | 49.05 | 48.68 | 46.09 | 34.12 | 23.44 | 22.35 | ▲5.6% | +21.5% |
| Margins | ||||||||
Gross margin87th pct in Healthcare | 91.4% | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | ▼1.5pp | −0.6pp |
Operating margin | −12.4% | −113.7% | −107.1% | −79.2% | −122.8% | −192.1% | ▼6.7pp | +78.4pp |
Net margin20th pct in Healthcare | −26.3% | −139.8% | −140.4% | −123.6% | −170.6% | −230.7% | ▲0.5pp | +90.9pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was UroGen Pharma's revenue last fiscal year?
UroGen Pharma reported revenue of $109.8M in fiscal 2025, up 21.4% from fiscal 2024.
What was UroGen Pharma's net income?
UroGen Pharma reported net income of −$153.5M in fiscal 2025, a net margin of −139.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

